Deerfield, Ill. - May 2, 2017
Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has declared a 23 percent increase in the company’s quarterly dividend rate, from the previous rate of $0.13 per Baxter common share to $0.16 per share. The dividend is payable on July 3, 2017 to stockholders of record as of June 2, 2017.
“Baxter is pleased to raise our quarterly dividend rate, which reflects the company’s strong financial performance and commitment to enhancing shareholder value,” said José (Joe) E. Almeida, chairman and chief executive officer. “This new rate aligns with our disciplined approach to capital allocation, as we strategically balance reinvestment in the business to drive sustainable growth along with returning value to our shareholders.”
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's dividend. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company’s financial position, including cash flows; future decisions of the board of directors of the company to continue payments to shareholders in the form of a dividend on a quarterly or other basis relative to alternative uses of funds; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.